Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC? Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC?

Nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical surgery for high-risk, muscle-invasive urothelial carcinoma, new research suggests.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news